Search

Your search keyword '"Donoso Trenado, Víctor"' showing total 45 results
Start Over Author "Donoso Trenado, Víctor"
45 results on '"Donoso Trenado, Víctor"'

1. Structural heart transcatheter interventions in orthotopic cardiac transplant and left ventricular assist devices recipients: A nationwide study

Author

Blasco-Turrión, Sara, Crespo-Leiro, Maria Generosa, Donoso Trenado, Víctor, Chi Hion, Pedro Li, Díaz Molina, Beatriz, Roura, Gerard, Álvarez-Osorio, Manuel Pan, Gómez-Bueno, Manuel, Ortiz Bautista, Carlos, Diaz, Jose F., Garrido Bravo, Iris Paula, Moreno, Raúl, Sarnago-Cebada, Fernando, Salterain González, Nahikari, de la Torre Hernandez, Jose M., García del Blanco, Bruno, Farrero, Marta, Ortas Nadal, Rosario, Martin, Pedro, de La Fuente, Luis, Sanz-Sánchez, Jorge, Mirabet Pérez, Sònia, Alonso Fernández, Vanesa, Gómez Hospital, Joan Antoni, López Granados, Amador, Couto-Mallon, David, del Trigo Espinosa, María, Rangel Sousa, Diego, Zatarain-Nicolás, Eduardo, Arzamendi Aizpurua, Dabit, López Vilella, Raquel, San Román, J. Alberto, and Amat-Santos, Ignacio J.

Published
2024
Full Text
View/download PDF

10. Evolving Indications for Heart-Lung Transplant in Spain

Author

López-Vilella, Raquel, Gómez Bueno, Manuel, González Vílchez, Francisco, Solé Jover, Amparo, Laporta Hernández, Rosalía, Vicente Guillén, Rosario, González Román, Ana Isabel, Sánchez-Lázaro, Ignacio, Hernández Pérez, Francisco, Sales Badía, Gabriel, Córdoba Peláez, María Del Mar, Torregrosa Puerta, Salvador, Forteza Gil, Alberto, Donoso Trenado, Víctor, Martínez Dolz, Luis, Segovia Cubero, Javier, and Almenar Bonet, Luis

Published
2022
Full Text
View/download PDF

13. Comparative Temporal Analysis of Morbidity and Early Mortality in Heart Transplantation with Extracorporeal Membrane Oxygenation Support: Exploring Trends over Time.

Author

López-Vilella, Raquel, Pérez Guillén, Manuel, Guerrero Cervera, Borja, Gimeno Costa, Ricardo, Zarragoikoetxea Jauregui, Iratxe, Pérez Esteban, Francisca, Carmona, Paula, Heredia Cambra, Tomás, Talavera Peregrina, Mónica, Pajares Moncho, Azucena, Domínguez-Massa, Carlos, Donoso Trenado, Víctor, Martínez Dolz, Luis, Argente, Pilar, Castellanos, Álvaro, Martínez León, Juan, Torregrosa Puerta, Salvador, and Almenar Bonet, Luis

Subjects
HEART transplantation, SURVIVAL rate, HOSPITAL admission & discharge, KIDNEY failure, ARTIFICIAL respiration, EXTRACORPOREAL membrane oxygenation
Abstract

Background/Objectives: The direct bridge to urgent heart transplant (HT) with venoarterial extracorporeal membrane oxygenation (VA-ECMO) support has been associated with high morbidity and mortality. The objective of this study is to analyze the morbidity and mortality of patients transplanted with VA-ECMO and compare the presumed differences between various eras over a 17-year timeline. Methods: This is a prospective, observational study on consecutive patients stabilized with VA-ECMO and transplanted with VA-ECMO from July 2007 to December 2023 at a reference center (98 patients). Objective variables were mortality and morbidity from renal failure, venous thromboembolic disease (VTD), primary graft dysfunction (PGD), the need for tracheostomy, severe myopathy, reoperation, post-transplant ECMO, vascular complications, and sepsis/infection. Results: The percentage of patients who reached transplantation without the need for mechanical ventilation has increased over the periods studied. No significant differences were found between the study periods in 30-day mortality (p = 0.822), hospital discharge (p = 0.972), one-year mortality (p = 0.706), or five-year mortality (p = 0.797). Survival rates in these periods were 84%, 75%, 64%, and 61%, respectively. Comorbidities were very frequent, with an average of 3.33 comorbidities per patient. The most frequent were vascular complications (58%), the need for post-transplant ECMO (57%), and myopathy (55%). The development of myopathy and the need for post-transplant ECMO were higher in recent periods (p = 0.004 and p = 0.0001, respectively). Conclusions: VA-ECMO support as a bridge to HT allows hospital discharge for 3 out of 4 transplanted patients. This survival rate has not changed over the years. The comorbidities associated with this device are frequent and significant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Practical requirements for the development of an advanced cardiorenal unit

Author

Almenar-Boneta, Luis, primary, Sánchez-Lázaro, Ignacio, additional, Soldevila, Amparo, additional, López-Vilella, Raquel, additional, Donoso Trenado, Víctor, additional, Devesa, Ramón, additional, Carmona, Paula, additional, Tormo, Sergi, additional, Montero Hernández, María Jesús, additional, Hernández, Julio, additional, Martínez Dolzb, Luis, additional, and Sánchez-Pérezd, Pilar, additional

Published
2024
Full Text
View/download PDF

19. Therapeutic approach in heart failure with poor diuretic response: peripheral ultrafiltration vs. conventional treatment

Author

López‐Vilella, Raquel, primary, Guerrero Cervera, Borja, additional, Sánchez‐Lázaro, Ignacio, additional, Donoso Trenado, Víctor, additional, Soldevila Orient, Amparo, additional, Devesa Such, Ramón, additional, Martínez Dolz, Luis, additional, Sánchez Pérez, Pilar, additional, and Almenar Bonet, Luis, additional

Published
2023
Full Text
View/download PDF

21. Mortality after the first hospital admission for acute heart failure, de novo versus acutely decompensated heart failure with reduced ejection fraction

Author

López-Vilella, Raquel, Jover Pastor, Pablo, Donoso Trenado, Víctor, Sánchez-Lázaro, Ignacio, Barge-Caballero, Eduardo, Crespo-Leiro, María Generosa, Martínez-Dolz, Luis, Almenar-Bonet, Luis, López-Vilella, Raquel, Jover Pastor, Pablo, Donoso Trenado, Víctor, Sánchez-Lázaro, Ignacio, Barge-Caballero, Eduardo, Crespo-Leiro, María Generosa, Martínez-Dolz, Luis, and Almenar-Bonet, Luis

Abstract

[Abstract] It is not clear to date whether a first admission in heart failure (HF) marks a worse evolution in patients not previously diagnosed with HF ("de novo HF") than those already diagnosed as outpatients ("acutely decompensated HF"). The aim of the study was to analyze whether survival in patients admitted for de novo HF differs from the survival in those admitted for a first episode of decompensation but with a previous diagnosis of HF. This study includes an analysis of 1,728 patients admitted for decompensated HF during 9 years. Readmissions and patients with left ventricular ejection fraction ≥50% were excluded (finally, 524 patients analyzed). We compared de novo HF (n = 186) in patients not diagnosed with HF, although their structural heart disease was defined, versus acutely decompensated HF (n = 338). The clinical profiles in both groups were similar. The de novo HF group more frequently presented with normal right ventricular function, with less presence of severe tricuspid regurgitation. The probability of survival was low in both groups. Thus, the median life in the de novo HF group was 2.1 years and in the acutely decompensated HF group, 3.5 years. There was a lower probability of long-term survival in the de novo HF group (p = 0.035). The variables associated with mortality were age (p <0.0001), ischemic heart disease (p <0.0001), hypertension (p = 0.009), obesity (p = 0.025), diabetes (p = 0.001), and N-terminal pro-brain natriuretic peptide at admission (p <0.0001). A higher glomerular filtration rate was associated with better survival (p = 0.033). De novo HF was associated with a higher mortality than chronic HF with acute decompensation (hazard ratio 1.53, 95% confidence interval 1.03 to 2.27, p = 0.036). In conclusion, the first admission for HF decompensation in patients with no previous diagnosis of HF identifies a subgroup of patients with higher long-term mortality.

Published
2023

23. Heart failure risk scores in advanced heart failure patients: insights from the LEVO‐D registry.

Author

Codina, Pau, Dobarro, David, de Juan‐Bagudá, Javier, De Frutos, Fernando, Lupón, Josep, Bayes‐Genis, Antoni, Gonzalez‐Costello, José, Víctor Donoso‐Trenado, Víctor, Solé‐González, Eduard, Moliner‐Abós, Carlos, Garcia‐Pinilla, José Manuel, Lopez‐Fernandez, Silvia, Ruiz‐Bustillo, Sonia, Diez‐Lopez, Carles, Castrodeza, Javier, Méndez‐Fernández, Ana B, Vaqueriza‐Cubillo, David, Cobo‐Marcos, Marta, Tobar, Javier, and Sagasti‐Aboitiz, Igor

Subjects
DISEASE risk factors, HEART failure patients, HEART failure, BRAIN natriuretic factor, VENTRICULAR ejection fraction
Abstract

Aims: The prevalence of advanced heart failure (HF) is increasing due to the growing number of patients with HF and their better treatment and survival. There is a scarcity of data on the accuracy of HF web‐based risk scores in this selected population. This study aimed to assess mortality prediction performance of the Meta‐Analysis Global Group in Chronic HF (MAGGIC‐HF) risk score and the model of the Barcelona Bio‐HF Risk Calculator (BCN‐Bio‐HF) containing N terminal pro brain natriuretic peptide in HF patients receiving intermittent inotropic support with levosimendan as destination therapy. Methods and results: Four hundred and three advanced HF patients from 23 tertiary hospitals in Spain receiving intermittent inotropic support with levosimendan as destination therapy were included. Discrimination for all‐cause mortality was compared by area under the curve (AUC) and Harrell's C‐statistic at 1 year. Calibration was assessed by calibration plots comparing observed versus expected events based on estimated risk by each calculator. The included patients were predominantly men, aged 71.5 [interquartile range 64–78] years, with reduced left ventricular ejection fraction (27.5 ± 9.4%); ischaemic heart disease was the most prevalent aetiology (52.5%). Death rate at 1 year was 26.8%, while the predicted 1‐year mortality by BCN‐Bio‐HF and MAGGIC‐HF was 17.0% and 22.1%, respectively. BCN‐Bio‐HF AUC was 0.66 (Harrell's C‐statistic 0.64), and MAGGIC‐HF AUC was 0.62 (Harrell's C‐statistic 0.61). Conclusions: The two evaluated risk scores showed suboptimal discrimination and calibration with an underestimation of risk in advanced HF patients receiving levosimendan as destination therapy. There is a need for specific scores for advanced HF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO‐D registry

Author

Dobarro, David, primary, Donoso‐Trenado, Víctor, additional, Solé‐González, Eduard, additional, Moliner‐Abós, Carlos, additional, Garcia‐Pinilla, José Manuel, additional, Lopez‐Fernandez, Silvia, additional, Ruiz‐Bustillo, Sonia, additional, Diez‐Lopez, Carles, additional, Castrodeza, Javier, additional, Méndez‐Fernández, Ana B., additional, Vaqueriza‐Cubillo, David, additional, Cobo‐Marcos, Marta, additional, Tobar, Javier, additional, Sagasti‐Aboitiz, Igor, additional, Rodriguez, Miguel, additional, Escolar, Vanessa, additional, Abecia, Ana, additional, Codina, Pau, additional, Gómez‐Otero, Inés, additional, Pastor, Francisco, additional, Marzoa‐Rivas, Raquel, additional, González‐Babarro, Eva, additional, de Juan‐Baguda, Javier, additional, Melendo‐Viu, María, additional, de Frutos, Fernando, additional, and Gonzalez‐Costello, José, additional

Published
2023
Full Text
View/download PDF

29. Epidemiological study of tricuspid regurgitation after cardiac transplantation: does it influence survival?

Author

López-Vilella, Raquel, Paniagua-Martín, María J., González-Vílchez, Francisco, Donoso Trenado, Víctor, Barge-Caballero, Eduardo, Sánchez-Lázaro, Ignacio, Aller Fernández, Ana Vanesa, Martínez-Dolz, Luis, Crespo-Leiro, María Generosa, Almenar-Bonet, Luis, López-Vilella, Raquel, Paniagua-Martín, María J., González-Vílchez, Francisco, Donoso Trenado, Víctor, Barge-Caballero, Eduardo, Sánchez-Lázaro, Ignacio, Aller Fernández, Ana Vanesa, Martínez-Dolz, Luis, Crespo-Leiro, María Generosa, and Almenar-Bonet, Luis

Abstract

[Abstract] Background: Tricuspid valve disease is the most frequent valvulopathy after heart transplantation (HTx). Evidence for the negative effect of post-transplant tricuspid regurgitation (TR) on survival is contradictory. The aim of this study was to analyze the causes of post-transplant TR and its effect on overall mortality. Methods: This is a retrospective observational study of all transplants performed in two Spanish centers (1009 patients) between 2000 and 2019. Of the total number of patients, 809 had no TR or mild TR and 200 had moderate or severe TR. The etiology of TR was analyzed in all cases. Results: The prevalence of moderate and severe TR was 19.8%. The risk of mortality was greater when TR was caused by early primary graft failure (PGF) or rejection (p < 0.05). TR incidence was related to etiology: incidence of PGF-induced TR was higher in the first period, while TR due to rejection and undefined causes occurred more frequently in three periods: in the first year, in the 10-14-year period following HTx, and in the long term (16-18 years). In the multivariable analysis, TR was significantly associated with mortality/retransplantation (HR:1.04, 95% CI:1.01-1.07, p:0.02). Conclusion: The development of TR after HTx is relatively frequent. The annual incidence depends on TR severity and etiology. The risk of mortality is greater in severe TR due to PGF or rejection.

Published
2022

30. Epidemiological Study of Tricuspid Regurgitation After Cardiac Transplantation. Does it Influence Survival?

Author

López-Vilella, Raquel, primary, Paniagua-Martín, María J., additional, González-Vílchez, Francisco, additional, Donoso Trenado, Víctor, additional, Barge-Caballero, Eduardo, additional, Sánchez-Lázaro, Ignacio, additional, Aller Fernández, Ana V., additional, Martínez-Dolz, Luis, additional, Crespo-Leiro, María G., additional, and Almenar-Bonet, Luis, additional

Published
2022
Full Text
View/download PDF

31. Implicaciones pronósticas de la hipo e hiperpotasemia en la insuficiencia cardíaca aguda con fracción de eyección reducida. Análisis de la mortalidad cardiovascular y reingresos hospitalarios

Author

Laymito-Quispe, Rocío del Pilar, primary, López-Vilella, Raquel, additional, Sánchez-Lázaro, Ignacio, additional, Donoso-Trenado, Víctor, additional, Lozano-Edo, Silvia, additional, Martínez-Dolz, Luis, additional, and Almenar-Bonet, Luis, additional

Published
2022
Full Text
View/download PDF

33. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction

Author

López‐Vilella, Raquel, primary, Lozano‐Edo, Silvia, additional, Arenas Martín, Patricia, additional, Jover‐Pastor, Pablo, additional, Ezzitouny, Meryem, additional, Sorolla Romero, José, additional, Calvo Asensio, María, additional, Martínez‐Solé, Julia, additional, Guerrero Cervera, Borja, additional, Sánchez Martínez, José Carlos, additional, Donoso Trenado, Víctor, additional, Sánchez‐Lázaro, Ignacio, additional, Martinez Dolz, Luis, additional, and Almenar Bonet, Luis, additional

Published
2021
Full Text
View/download PDF

35. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.

Author

López‐Vilella, Raquel, Lozano‐Edo, Silvia, Arenas Martín, Patricia, Jover‐Pastor, Pablo, Ezzitouny, Meryem, Sorolla Romero, José, Calvo Asensio, María, Martínez‐Solé, Julia, Guerrero Cervera, Borja, Sánchez Martínez, José Carlos, Donoso Trenado, Víctor, Sánchez‐Lázaro, Ignacio, Martinez Dolz, Luis, and Almenar Bonet, Luis

Subjects
HEART failure patients, IRON deficiency
Abstract

Aims: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). Methods and results: We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin < 100 μg/L or ferritin 100–300 μg/L with transferrin saturation (TSAT) < 20%]. Clinical, laboratory, and echocardiographic parameters were analysed before and after administration. After FCM administration, overall ferritin, TSAT, and haemoglobin levels increased up to 5‐fold, 1.6‐fold, and 1.1‐fold, respectively, relative to baseline values in HF patients with reduced and preserved ejection fraction (P < 0.0001), with a greater increase in ferritin and TSAT in HFpEF patients. The left ventricular ejection fraction of the overall series improved by 8 percentage points in both types of HF (from 40% to 48%, P < 0.0001). The percentage of patients with normalization of right ventricular function increased by 6.9 points (from 74.1% to 81%) in HFpEF patients and by 6.4 points (from 53% to 59.4%) in the HFrEF subgroup (P < 0.0001). New York Heart Association functional status slightly improved, from a median of 2.4 (interquartile range, IQR: 2–2.7) to 1.9 (IQR: 1.5–2.5; P < 0.0001) after FCM in both types of HF. No changes were noted in plasma levels of liver enzymes, creatinine, or natriuretic peptide (P > 0.05). Conclusions: Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. ECG de agosto de 2018

Author

Andrés Lahuerta, Ana, primary, Osca Asensi, Joaquín, additional, and Donoso Trenado, Víctor José, additional

Published
2018
Full Text
View/download PDF

39. ECG, August 2018

Author

Andrés Lahuerta, Ana, primary, Osca Asensi, Joaquín, additional, and Donoso Trenado, Víctor José, additional

Published
2018
Full Text
View/download PDF

41. Implicaciones pronósticas de la hipo e hiperpotasemia en la insuficiencia cardíaca aguda con fracción de eyección reducida. Análisis de la mortalidad cardiovascular y reingresos hospitalarios

Author

Laymito-Quispe, Rocío del Pilar, López-Vilella, Raquel, Sánchez-Lázaro, Ignacio, Donoso-Trenado, Víctor, Lozano-Edo, Silvia, Martínez-Dolz, Luis, and Almenar-Bonet, Luis

Abstract

Las alteraciones del potasio constituyen un problema clínico de gran magnitud en la insuficiencia cardíaca (IC) descompensada. Este estudio pretende valorar las implicaciones pronósticas de la hipo e hiperpotasemia al ingreso por IC aguda en la mortalidad cardiovascular y reingresos hospitalarios.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results